225Ac-DOTA-LM3 Research for Neuroendocrine Tumors (NETs)
An evidence-based overview of research examining 225Ac-DOTA-LM3 in the context of neuroendocrine tumors (nets). This page synthesizes findings from peer-reviewed literature.
Research Summary
225Ac-DOTA-LM3 is primarily investigated for SSTR-positive neuroendocrine tumors. The first-in-humans study of the related antagonist 177Lu-DOTA-LM3 (n=51) reported an 85.1% disease control rate with 36.2% partial responses, including responses in patients with low or no SSTR agonist binding. The antagonist binding mechanism provides higher tumor uptake compared to agonist-based therapies.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. 225Ac-DOTA-LM3 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.